UKHSA’s flagship SIREN study enters new phase to continue surveillance of respiratory pathogens

The next phase of the study will be known as SIREN 2.0 and began in September 2023.

J&J’s Actelion buyout pays off again with approval of Opsynvi in pulmonary arterial hypertension

Johnson & Johnson scored an FDA approval for Opsynvi, a combo of the endothelin receptor antagonist Opsumit and the phosphodiesterase 5 inhibitor tadalafil, for the

March 26, 2024

New Two-Tier System to Weed Out Some Pediatric Heart Surgery Centers

Professional societies agreed that U.S. centers performing pediatric and congenital heart surgery should be formally reorganized into two tiers with volume requirements designed to maintain

September 30, 2023

Space experiment shows faster maturation of brain organoids in microgravity

Microgravity is known to alter the muscles, bones, the immune system and cognition, but little is known about its specific impact on the brain.

December 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.